Back to discover
Drug

Testosterone

In clinical development
ClassAndrogen Receptor agonistActively researchedLate-stage developmentRising momentum
Also known as 17beta-hydroxy-4-androsten-3-one, AndroGel, Androderm, Aveed+42 more

17beta-hydroxy-4-androsten-3-one, AndroGel, Androderm, Aveed, Axiron, Azmiro, Delatest, Delatestadiol, Delatestryl, Dep Androgyn, Depo-Testadiol, Depo-Testosterone, Depotest, Depotestogen, Duo-Cyp, Dura-Dumone, Duratest, Duratestrin, Estra-Testrin, Everone, Fortesta, Histerone, Jatenzo, Kyzatrex, Meditest, Natesto, Striant, Synovex H, Testamone-100, Testim, Testoderm, Testolin, Testopel, Testosterone Cypionate, Testosterone Enanthate, Testosterone Propionate, Testro, Testro AQ, Tlando, Undecatrex, Vogelxo, Xyosted, Testosteron, Testosterona, Testostérone, Testosteronum.

39
Research papers
20
Active clinical trials
Androgen receptor
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Neurology of Androgens and Androgenic Supplements.

Research2025-06-03Current neurology and neuroscience reports

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Testosterone
Aliases & brands
17beta-hydroxy-4-androsten-3-oneAndroGelAndrodermAveedAxironAzmiroDelatestDelatestadiolDelatestrylDep AndrogynDepo-TestadiolDepo-TestosteroneDepotestDepotestogenDuo-CypDura-DumoneDuratestDuratestrinEstra-TestrinEveroneFortestaHisteroneJatenzoKyzatrexMeditestNatestoStriantSynovex HTestamone-100TestimTestodermTestolinTestopelTestosterone CypionateTestosterone EnanthateTestosterone PropionateTestroTestro AQTlandoUndecatrexVogelxoXyostedTestosteronTestosteronaTestostéroneTestosteronum
RxNorm CUI
10379
ChEMBL ID
CHEMBL386630
ATC codes
G03BA03
UNII
3XMK78S47O
Primary mechanism
Androgen Receptor agonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Androgen receptor
AR · P10275
AGONISTAndrogen Receptor agonist

Clinical trials

179 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
179
registered trials across all phases
LATEST COMPLETION 2026
20
Active studies
17
Recruiting
90
Late-stage (III+)
118
Completed
41
Discontinued
PHASE DISTRIBUTIONn = 179
Early Phase 16Phase 124Phase 1 / 23Phase 256Phase 2 / 39Phase 322Phase 439Phase N / A20

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

39 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
19952025
Most influential
Recent papers
Major research themes8
Polycystic Ovary Syndrome7Testosterone5Estradiol4Gonadal Steroid Hormones4Transgender Persons4Androgens2Body Mass Index2Glucagon-Like Peptide-1 Receptor Agonists2
Journals, researchers & institutions
Top journals
  • The Journal of clinical endocrinology and metabolism5
  • Frontiers in endocrinology4
  • Andrology3
  • Nutrients3
  • International journal of molecular sciences2
  • The Journal of clinical investigation2
Leading researchers
  • den Heijer M3
  • Bubley GJ2
  • Clarke SA2
  • Corona G2
  • Vanderschueren D2
  • Wang C2
  • Wiepjes CM2
  • Abbara A1
Leading institutions
free-text, unnormalised
  • Baylor College of Medicine2
  • Center of Expertise on Gender Dysphoria2
  • Imperial College London2
  • Medical School2
  • School of Medical Sciences2
  • School of Medicine2

Related diseases

9 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 13 of the same disease areas as Testosterone in the shared literature.

13 shared diseases9 shared papers

Studied across 17 of the same disease areas as Testosterone in the shared literature.

17 shared diseases6 shared papers

Studied across 8 of the same disease areas as Testosterone in the shared literature.

8 shared diseases6 shared papers

Studied across 12 of the same disease areas as Testosterone in the shared literature.

12 shared diseases2 shared papers

Studied across 6 of the same disease areas as Testosterone in the shared literature.

6 shared diseases5 shared papers

Studied across 9 of the same disease areas as Testosterone in the shared literature.

9 shared diseases3 shared papers

Studied across 11 of the same disease areas as Testosterone in the shared literature.

11 shared diseases1 shared paper

Studied across 11 of the same disease areas as Testosterone in the shared literature.

11 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials